Literature DB >> 6287848

Syndromes of thyroid hormone resistance.

S Refetoff.   

Abstract

Resistance to the action of thyroid hormone can involve both peripheral tissues and the pituitary (global resistance), the pituitary only or peripheral tissues alone. Global resistance is of variable severity and has been observed in more than 60 individuals, the majority occurring in 17 families. Affected subjects are commonly eumetabolic and have goiters, elevated plasma levels of total and free thyroxine and triiodothyronine, normal thyroid hormone metabolism, and normal serum TSH levels (albeit high for the corresponding levels of thyroid hormone). A variable degree of delayed bone maturation, mental retardation, learning disabilities, and hearing defects have been reported; and a variety of treatment regimens, most of which are aimed at reducing the level of plasma hormones and/or goiter, have been attempted before the correct diagnosis has been reached. The clinical disorder is equally common in males and females and appears to be due to one or more autosomal gene mutations. The causes for the hormone resistance may be heterogeneous, either influencing the receptor for thyroid hormones or some unidentified steps in hormone action. At present, the diagnosis is one of exclusion; no effective therapy is available, and all measures designed to lower serum thyroid hormone levels should be avoided.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6287848     DOI: 10.1152/ajpendo.1982.243.2.E88

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  17 in total

1.  Clinical hyperthyroidism due to non-neoplastic inappropriate thyrotrophin secretion.

Authors:  A W Chan; I A MacFarlane; C van Heyningen; P M Foy
Journal:  Postgrad Med J       Date:  1990-09       Impact factor: 2.401

Review 2.  Brain meets body: the blood-brain barrier as an endocrine interface.

Authors:  William A Banks
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

3.  Hyperactivity and learning deficits in transgenic mice bearing a human mutant thyroid hormone beta1 receptor gene.

Authors:  M P McDonald; R Wong; G Goldstein; B Weintraub; S Y Cheng; J N Crawley
Journal:  Learn Mem       Date:  1998 Sep-Oct       Impact factor: 2.460

Review 4.  Insulin in the brain: there and back again.

Authors:  William A Banks; Joshua B Owen; Michelle A Erickson
Journal:  Pharmacol Ther       Date:  2012-07-17       Impact factor: 12.310

5.  Anti-iodothyronine autoantibodies in a girl with hyperthyroidism due to pituitary resistance to thyroid hormones.

Authors:  A Crinò; P Borrelli; R Salvatori; D Cortelazzi; R Roncoroni; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

6.  Kindred S thyroid hormone receptor is an active and constitutive silencer and a repressor for thyroid hormone and retinoic acid responses.

Authors:  A Baniahmad; S Y Tsai; B W O'Malley; M J Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

7.  Generalized thyroid hormone resistance: identification of an arginine to cystine mutation in codon 315 of the c-erb A beta thyroid hormone receptor.

Authors:  K D Burman; Y Y Djuh; D Nicholson; P Rhooms; L Wartofsky; H G Fein; S J Usala; E H Hao; W E Bradley; J Berard
Journal:  J Endocrinol Invest       Date:  1992-09       Impact factor: 4.256

Review 8.  The clinician and the thyroid.

Authors:  H J Biersack; A Hotze
Journal:  Eur J Nucl Med       Date:  1991

9.  Abnormal daily periodicity of serum thyrotropin (TSH) and evidence for defective TSH suppression in a case of non-neoplastic syndrome of inappropriate TSH secretion.

Authors:  S Benvenga; G A Sobbrio; F Vermiglio; L Li Calzi; S Cannavò; F Consolo; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

10.  An arginine to histidine mutation in codon 311 of the C-erbA beta gene results in a mutant thyroid hormone receptor that does not mediate a dominant negative phenotype.

Authors:  M E Geffner; F Su; N S Ross; J M Hershman; C Van Dop; J B Menke; E Hao; R K Stanzak; T Eaton; H H Samuels
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.